|Back to main|
uniQure prices IPO at $17, above the range
By: Renaissance Capital
uniQure, a biotech developing gene therapies for the treatment of orphan diseases, raised $92 million by offering 5.4 million shares at $17, above the range of $13-$15. uniQure plans to list on the NASDAQ under the symbol QURE. Jefferies and Leerink Partners acted as lead managers on the deal.